Global vaccine market

1. Global Vaccine Market Forecast to 2017
© RNCOS Page 1

2. Global Vaccine Market Forecast to 2017
© RNCOS Page 2
Table of Contents
1. Analyst View
2. Research Methodology
3. Global Vaccine Market Outlook to 2017
4. Major Vaccines: Current and Future Market Analysis
4.1 Pneumococcal
4.2 Influenza
4.3 Cancer
4.4 Polio
4.5 Varicella
4.6 Rotavirus
4.7 Meningococcal
4.8 DTP
4.9 Hepatitis
4.10 Measles, Mumps, and Rubella (MMR)
4.11 Japanese Encephalitis
4.12 Tuberculosis
4.13 Malaria
4.14 Rabies
4.15 Typhoid
4.16 HIV
5. Key Geographical Markets
5.1 US
5.2 Europe
5.3 Japan
5.4 China
5.5 India
5.6 Brazil
6. Competitive Landscape
6.1 GSK
6.2 Sanofi-Pasteur
6.3 Pfizer
6.4 Merck
6.5 Novartis
6.6 Emergent Biosolutions
6.7 AstraZeneca Plc.
6.8 Baxter International Inc.
6.9 BioCSL (CSL Biotherapies)
6.10 Dendreon Corporation
6.11 Takeda Pharmaceutical Company Limited
6.12 Crucell

3. Global Vaccine Market Forecast to 2017
© RNCOS Page 3
List of Figures:
Figure 3-1: Global - Vaccine Market (Billion US$), 2012-2017
Figure 4-1: Global - Causes of Deaths in Children (<5 Years) among Low-income Countries (%), 2011
Figure 4-2: Global - Pneumococcal Vaccine Market (Billion US$), 2012-2017
Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2012-2017
Figure 4-4: Global - Cancer Vaccine Market (Billion US$), 2012-2017
Figure 4-5: Global - Polio Vaccine Market (Billion US$), 2012-2017
Figure 4-6: Global - Varicella Vaccine Market (Billion US$), 2012-2017
Figure 4-7: Global - Rotavirus Vaccine Market (Billion US$), 2012-2017
Figure 4-8: Global - Meningococcal Vaccine Market (Billion US$), 2012-2017
Figure 4-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010)
Figure 4-10: Global - Number of nTetanus Incidences by Region (2009 & 2010)
Figure 4-11: Global - Number of tTetanus Incidences by Region (2009 & 2010)
Figure 4-12: Global - Number of Pertussis Incidences by Region (2009 & 2010)
Figure 4-13: Global - DTP Vaccine Market (Billion US$), 2012-2017
Figure 4-14: Global - Hepatitis Vaccine Market (Million US$), 2012-2017
Figure 4-15: Global - Number of Measles Incidences by Region (2009 & 2010)
Figure 4-16: Global - Number of Mumps Incidences by Region (‘000), 2009 & 2010
Figure 4-17: Global - Number of Rubella Incidences by Region (2009 & 2010)
Figure 4-18: Global - MMR Vaccine Market (Million US$), 2012-2017
Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2012-2017
Figure 4-20: Global - Sources for Funding in HIV Vaccine R&D (%), 2011
Figure 5-1: Global - Vaccine Market by Region (%), 2012
Figure 5-2: Global - Vaccine Market by Region (%), 2017
Figure 5-3: US - Vaccine Market (Billion US$), 2012-2017
List of Tables:
Table 4-1: Pneumococcal Vaccine Market - Key Players and Vaccines
Table 4-2: Key Pneumococcal Vaccines in Pipeline
Table 4-3: Influenza Vaccine Market - Key Players and Vaccines
Table 4-4: Key Influenza Vaccines in Pipeline
Table 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)
Table 4-6: Cancer Vaccine Market - Key Players and Vaccines
Table 4-7: Key Cancer Vaccines in Pipeline
Table 4-8: Polio Vaccine Market - Key Players and Vaccines
Table 4-9: Key Polio Vaccines in Pipeline
To see full list of figures & tables visit:
http://www.rncos.com/Report/IM491_fig.htm

4. Global Vaccine Market Forecast to 2017
© RNCOS Page 4
Pneumococcal
Pneumococcal disease causes a broad range of
infections in people around the world. The
bacterium responsible for the disease,
pneumococcus causes pneumonia, meningitis,
and sepsis (serious blood infection) and takes
the lives of more than half a million children
each year worldwide with Africa and Asia being
the sensitive zone.
Pneumonia is the most common form of serious
pneumococcal disease and accounts for xx% of
children’s deaths in developing countries.
Around xx% of the cases affect children under
the age of 5 Years and at risk are elderly and
children under 2 Years.
Figure 4-1: Global - Causes of Deaths in
Children (<5 Years) among Low-income
Countries (%), 2011
Pneumonia Diarrhoea
Malaria Prematurity
Birth Asphyxia Neonatal Sepsis
Congenital Abnormalities HIV/AIDS
Injuries Measles
Others
Source:
Pfizer’s Prevnar 13/Prevenar 13 is the most
selling vaccine in the market. The vaccine
generated revenue of around US$ xx Billion in
2012. The vaccine is a 13-valent pneumococcal
conjugate vaccine for the prevention of various
syndromes of pneumococcal disease in infants
and young children and in adults 50 years of age
and older
Prevnar 13/Prevenar 13 for use in infants and
young children is marketed in the U.S. for the
prevention of invasive pneumococcal disease
caused by the 13 serotypes in Prevnar 13 and
otitis media caused by the seven serotypes in
Prevnar, and in the EU and many other
international markets for the prevention of
invasive pneumococcal disease, otitis media
and pneumococcal pneumonia caused by the
vaccine serotypes
Prevenar 13 for use in adults 50 years of age
and older has been approved in over 55
countries. On January 25, 2013, the US FDA
granted approval for the expansion of Prevnar
13 for use in children ages 6 through 17 years
for active immunization for the prevention of
invasive disease caused by the 13 vaccine
serotypes. EU approval for use in children 6
through 17 years of age was received on
January 7, 2013.
Other important products in the pneumococcal
vaccine market include GSK’s Synflorix and
Merck’s Pneumovax 23 which generated
estimated revenue of around US$ xx Million
each. Cont…
SSaammppllee SSeeccttiioonnss ffrroomm tthhee RReeppoorrtt
To purchase the full report visit:
http://www.rncos.com/Report/IM491.htm

5. Global Vaccine Market Forecast to 2017
© RNCOS Page 5
India
India, with the world’s second-largest
population and a high incidence rate of all
major adult and pediatric diseases is a huge
potential market for all leading vaccine
manufacturers. Several multinational
companies consider India as the key market for
vaccines with the national immunization
program (NIP) gaining more popularity. At
present, exports have a major share (around
xx%) in the Indian vaccine market.
Figure 5-7: India - Share of Domestic
Consumption and Exports in Vaccine Market
(2012)
Domestic Consumption Exports
Source: RNCOS
The vaccine market in India is at an early growth
stage, but due to factors like rising
immunization programmes by government and
increased disease awareness, the sector is
expected to perform well in the future. The
Global Alliance for Vaccines and Immunisation
(GAVI) has also proposed a US$ xx Million grant
to the Indian Government for immunization of
xx Million newborns with pentavalent vaccines
which, if accepted, will lead to additional
business from India.
Moreover, the country offers good research
climate and better services to global players in
the vaccine market. Taking into consideration
all the above-mentioned factors, major industry
players are expected to enter the Indian market
through collaborations or agreements to tap
the sector.
Growth in the Indian vaccine market is also
anticipated to be driven by both the strong
demand in the domestic market as well as an
increase in exports owing to an increase in
demand from the WHO, GAVI, and the
developing countries. On the back of these
factors, Indian vaccine market is expected to
grow at a CAGR of around xx% between 2012
and 2017 to record around US$ xx Billion.
At present, a large chunk of the market is
owned by domestic firms including Serum
Institute of India, Shantha Biotech, Indian
Immunological, Panacea Biotech,
Venketeshwara Hatcheries, and many more.
Among the foreign players, GSK, Sanofi-Pasteur,
Merck & Co., and others dominate the market.
Cont…
To purchase the full report visit:
http://www.rncos.com/Report/IM491.htm

6. Global Vaccine Market Forecast to 2017
© RNCOS Page 6
Research Methodology
Our dedicated team of industry experts intensively monitored and analyzed the healthcare industry
scenario of almost all major economies in the world. The team found that due to rising healthcare cost
and increasing prevalence of various severe diseases, the consumer behavior has changed drastically.
Now, consumers prefer vaccines as preventive measures rather than relying upon treatments. This has
boosted the demand of vaccines in the world, resulting in a generation of greater profits for vaccine
players. This led us to study the global vaccine industry and explore various growth opportunities in the
market. The snapshot of our thorough research approach includes:
Secondary Research
The research process begins with exhaustive secondary research on internal and external sources being
carried out to source qualitative and quantitative information relating to each market. The secondary
research sources that are typically referred to include, but are not limited to:
• Company websites, annual reports, financial reports, broker reports, investor presentations and
SEC Filings
• Industry trade journals, Internal and external proprietary databases (EIU, One-source, Nexis,
Hoovers etc.)
• National government documents, statistical databases and market reports
• News articles, press releases and web-casts specific to the companies operating in the market
Primary Research
RNCOS conducts numerous primary interviews every year with industry participants and commentators
in order to validate its data and analysis. A typical research interview fulfills the following functions:
• It provides first-hand information on the market size, market trends, growth trends, competitive
landscape, future outlook, etc.
• Helps in validating and strengthening the secondary research findings
• Further develops the Analysis Team's expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews
for each market, category, segment and sub-segment across geographies.
Estimations and Forecasts
The forecast provided is based on the result of our economic and judgmental analysis and past drivers,
challenges, and opportunities for expansion. While forecasting, we have given due consideration to the
current industry trends. In this way, our report depicts the most unbiased picture of the global vaccine
market.

7. Global Vaccine Market Forecast to 2017
© RNCOS Page 7
ABOUT
Established in 2002, RNCOS is a premier source of healthcare research and information provider. We
bring first-hand information and prudent analysis on the healthcare industry, technologies, economic
and non-economic market parameters, potential markets, and key competitors, to help clients identify
prospective growth areas and gain competitive edge.
All our research solutions are supported by robust, evidence-based analytics grounded by extensive
primary and secondary research. They not only provide the most up-to-date market figures, forecasts,
and pipeline data, but offers valuable insights on successes and failures in the ever-competitive
healthcare industry.
Our reports provide strategic information for investment bankers, companies, management consultants,
trade associations, corporate executives and business analysts. Our work helps them to support critical
business decisions such as, entering new markets, launching and enhancing products, making
acquisitions or strategic investments, unseating competitors and more.
WORK PROCESS
Contact Information
B 129, Sector 6, Noida, India
Ph.: + 91 (120) 4224700 Extn. 203/208
Fax: + 91 (120) 4224707
Email: marketing@rncos.com
Website: www.rncos.com

8. Global Vaccine Market Forecast to 2017
© RNCOS Page 8
Disclaimer
The findings, conclusions and recommendations that RNCOS delivers are based on
information gathered in good faith from both primary and secondary sources. Neither the
company nor any of its employees makes any warranty, express or implied, including the
warranties of merchantability and fitness for a particular purpose, or assumes any legal
liability or responsibility for the accuracy, completeness, or usefulness of any information,
apparatus, product, or process disclosed, or represents that its use would not infringe
privately owned rights.
No part of this publication may be reproduced, stored in a retrieval system or transmitted in
any form by any means, electronic, mechanical, photocopying, recording or otherwise,
without the prior permission of RNCOS. Such protected material, however, may be used
under the terms of "fair use" as defined in the copyright laws, which generally permits use
for non-commercial educational purposes such as teaching, research, criticism, and news
reporting.
Unless otherwise stated, the copyright, database rights, and other similar rights of this
publication are solely owned by RNCOS. You are permitted to print or download extracts
from this material for your personal use only. None of this material may be used for any
commercial or public use.
No part of research material appearing may be reproduced, stored in or transmitted on any
other Website without written permission of RNCOS and any payments of a specified fee.
Requests to republish any material may be sent to us and it is our sole discretion to allow it
or not.